{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:45:19Z","timestamp":1694652319909},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T00:00:00Z","timestamp":1456272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00105-016-3768-4","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T10:18:42Z","timestamp":1456309122000},"page":"249-264","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapie der Vitiligo"],"prefix":"10.1007","volume":"67","author":[{"given":"M.","family":"Meurer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,24]]},"reference":[{"key":"3768_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","volume":"20","author":"A Ta\u00efeb","year":"2007","unstructured":"Ta\u00efeb A, Picardo M, VETF Members (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20:27\u201335","journal-title":"Pigment Cell Res"},{"key":"3768_CR2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/0019-5154.152508","volume":"60","author":"LN Sangma","year":"2015","unstructured":"Sangma LN, Nath J, Bhagabati D (2015) Quality of life and psychological morbidity in vitiligo patients: a study in a teaching hospital from north-East India. Indian J Dermatol 60:142\u2013146","journal-title":"Indian J Dermatol"},{"key":"3768_CR3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0190-9622(90)70028-G","volume":"22","author":"JR Porter","year":"1990","unstructured":"Porter JR, Beuf AH, Lerner AB, Nordlund JJ (1990) The effect of vitiligo on sexual relationships. J Am Acad Dermatol 22:221\u2013222","journal-title":"J Am Acad Dermatol"},{"key":"3768_CR4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/pcmr.12354","volume":"28","author":"V Eleftheriadou","year":"2015","unstructured":"Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, Katayama I, Anbar T, Abdallah M, Benzekri L, Gauthier Y, Harris J, Silva de Castro CC, Pandya A, Goh BK, Lan CC, Oiso N, Al Issa A, Esmat S, Le Poole C, Lee AY, Parsad D, Ta\u00efeb A, Picardo M, Ezzedine K (2015) Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus. Pigment Cell Melanoma Res 28:363\u2013369","journal-title":"Pigment Cell Melanoma Res"},{"key":"3768_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","volume":"168","author":"A Ta\u00efeb","year":"2013","unstructured":"Ta\u00efeb A, Alomar A, B\u00f6hm M, Dell\u2019Anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M (2013) Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 168:5\u201319","journal-title":"Br J Dermatol"},{"key":"3768_CR6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bjd.12669","volume":"170","author":"F Meredith","year":"2013","unstructured":"Meredith F, Abbott R (2013) Vitiligo: an evidence-based update. Report of the 13th Evidence Based Update Meeting, 23 May 2013, Loughborough, U.K. Br J Dermatol 170:565\u2013570","journal-title":"Br J Dermatol"},{"key":"3768_CR7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N (2015) Vitiligo. Lancet 386:74\u201384","journal-title":"Lancet"},{"key":"3768_CR8","first-page":"CD003263","volume":"25","author":"ME Whitton","year":"2006","unstructured":"Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U (2006) Interventions for vitiligo. Cochrane Database Syst Rev 25:CD003263","journal-title":"Cochrane Database Syst Rev"},{"key":"3768_CR9","first-page":"CD003263","volume":"20","author":"ME Whitton","year":"2010","unstructured":"Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonz\u00e1lez U (2010) Interventions for vitiligo. Cochrane Database Syst Rev 20:CD003263","journal-title":"Cochrane Database Syst Rev"},{"key":"3768_CR10","first-page":"CD003263","volume":"2","author":"ME Whitton","year":"2015","unstructured":"Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, Gonz\u00e1lez U, Jiyad Z, Eleftheriadou V, Ezzedine K (2015) Interventions for vitiligo. Cochrane Database Syst Rev 2:CD003263","journal-title":"Cochrane Database Syst Rev"},{"key":"3768_CR11","doi-asserted-by":"crossref","unstructured":"Schild M, Meurer M (2016) Vitiligo: Klinik und Pathogenese. Hautarzt\u00a067: 173-188","DOI":"10.1007\/s00105-015-3751-5"},{"key":"3768_CR12","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jaad.2012.01.038","volume":"69","author":"E Lilly","year":"2013","unstructured":"Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV (2013) Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol 69:e11\u2013e18","journal-title":"J Am Acad Dermatol"},{"key":"3768_CR13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H (2004) Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 140:677\u2013683","journal-title":"Arch Dermatol"},{"key":"3768_CR14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMcp0804388","volume":"360","author":"A Ta\u00efeb","year":"2009","unstructured":"Ta\u00efeb A, Picardo M (2009) Clinical practice. Vitiligo. N Engl J Med 360:160\u2013169","journal-title":"N Engl J Med"},{"key":"3768_CR15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/0378-6323.90945","volume":"78","author":"IH Hamzavi","year":"2012","unstructured":"Hamzavi IH, Lim HW, Syed ZU (2012) Ultraviolet-based therapy for vitiligo: what\u2019s new? Indian J Dermatol Venereol Leprol 78:42\u201348","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"3768_CR16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1365-2133.2012.11111.x","volume":"167","author":"N Geel Van","year":"2012","unstructured":"Van Geel N, Speeckaert R, De Wolf J, Bracke S, Chevolet I, Brochez L, Lambert J (2012) Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol 167:1017\u20131024","journal-title":"Br J Dermatol"},{"key":"3768_CR17","first-page":"1532","volume":"134","author":"MD Njoo","year":"1998","unstructured":"Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM (1998) Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 134:1532\u20131540","journal-title":"Arch Dermatol"},{"key":"3768_CR18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000065845","volume":"205","author":"DA Smith","year":"2002","unstructured":"Smith DA, Tofte SJ, Hanifin JM (2002) Repigmentation of vitiligo with topical tacrolimus. Dermatology 205:301\u2013303","journal-title":"Dermatology"},{"key":"3768_CR19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/09546630601028711","volume":"17","author":"N Sendur","year":"2006","unstructured":"Sendur N, Karaman G, Sani\u00e7 N, Savk E (2006) Topical pimecrolimus: a new horizon for vitiligo treatment? J Dermatolog Treat 17:338\u2013342","journal-title":"J Dermatolog Treat"},{"key":"3768_CR20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000065863","volume":"205","author":"M Meurer","year":"2002","unstructured":"Meurer M, F\u00f6lster-Holst R, Wozel G, Weidinger G, Junger M, Br\u00e4utigam M (2002) Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 205:271\u2013277","journal-title":"Dermatology"},{"key":"3768_CR21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1468-3083.2012.04498.x","volume":"27","author":"KY Lee","year":"2013","unstructured":"Lee KY, Jeon SY, Hong JW, Choi KW, Lee CY, Choi SJ, Kim JH, Song KH, Kim KH (2013) Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-\u03b1-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol 27:609\u2013616","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3768_CR22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2133.2005.06739.x","volume":"153","author":"CC Lan","year":"2005","unstructured":"Lan CC, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS (2005) FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 153:498\u2013505","journal-title":"Br J Dermatol"},{"key":"3768_CR23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/dth.12008","volume":"25","author":"IV Korobko","year":"2012","unstructured":"Korobko IV (2012) Review of current clinical studies of vitiligo treatments. Dermatol Ther 25:17\u201327","journal-title":"Dermatol Ther"},{"key":"3768_CR24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/09546630903266761","volume":"21","author":"O K\u00f6se","year":"2010","unstructured":"K\u00f6se O, Arca E, Kurumlu Z (2010) Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat 21:133\u2013139","journal-title":"J Dermatolog Treat"},{"key":"3768_CR25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/0378-6323.90949","volume":"78","author":"S Kathuria","year":"2012","unstructured":"Kathuria S, Khaitan BK, Ramam M, Sharma VK (2012) Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1\u2009% tacrolimus ointment vs 0.05\u2009% fluticasone propionate cream. Indian J Dermatol Venereol Leprol 78:68\u201373","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"3768_CR26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0625.2008.00756.x","volume":"18","author":"R Aschoff","year":"2009","unstructured":"Aschoff R, Schwanebeck U, Br\u00e4utigam M, Meurer M (2009) Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1\u2009% in patients with mild-to-moderate atopic dermatitis. Exp Dermatol 18:24\u201329","journal-title":"Exp Dermatol"},{"key":"3768_CR27","first-page":"167","volume":"10","author":"M Czarnecka-Operacz","year":"2012","unstructured":"Czarnecka-Operacz M, Jenerowicz D (2012) Topical calcineurin inhibitors in the treatment of atopic dermatitis \u2013 an update on safety issues. J Dtsch Dermatol Ges 10:167\u2013172","journal-title":"J Dtsch Dermatol Ges"},{"key":"3768_CR28","first-page":"89","volume":"20","author":"SM Wazir","year":"2010","unstructured":"Wazir SM, Paracha MM, Khan SU (2010) Efficacy and safety of topical mometasone furoate 0.01\u2009% vs. tacrolimus 0.03\u2009% and mometasone furoate 0.01\u2009% in vitiligo. J Pak Assoc Dermatol 20:89\u201392","journal-title":"J Pak Assoc Dermatol"},{"key":"3768_CR29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000078462","volume":"208","author":"M Meurer","year":"2004","unstructured":"Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M; CASM-DE-01 Study Group (2004) Long-term efficacy and safety of pimecrolimus cream 1\u2009% in adults with moderate atopic dermatitis. Dermatology 208:365\u2013372","journal-title":"Dermatology"},{"key":"3768_CR30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archderm.143.5.578","volume":"143","author":"SS Yones","year":"2007","unstructured":"Yones SS, Palmer RA, Garibaldinos TM, Hawk JL (2007) Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy. Arch Dermatol 143:578\u2013584","journal-title":"Arch Dermatol"},{"key":"3768_CR31","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","volume":"135","author":"M Cavali\u00e9","year":"2015","unstructured":"Cavali\u00e9 M, Ezzedine K, Fontas E, Montaudi\u00e9 H, Castela E, Bahadoran P, Ta\u00efeb A, Lacour JP, Passeron T (2015) Maintenance therapy of adult vitiligo with 0.1\u2009% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol 135:970\u2013974","journal-title":"J Invest Dermatol"},{"key":"3768_CR32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2008.08923.x","volume":"160","author":"R Kapoor","year":"2009","unstructured":"Kapoor R, Phiske MM, Jerajani HR (2009) Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol 160:861\u2013863","journal-title":"Br J Dermatol"},{"key":"3768_CR33","first-page":"57","volume":"145","author":"AR Hossani-Madani","year":"2010","unstructured":"Hossani-Madani AR, Halder RM (2010) Topical treatment and combination approaches for vitiligo: new insights, new developments. G Ital Dermatol Venereol 145:57\u201378","journal-title":"G Ital Dermatol Venereol"},{"key":"3768_CR34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2174\/138945008783954970","volume":"9","author":"SA Birlea","year":"2008","unstructured":"Birlea SA, Costin GE, Norris DA (2008) Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 9:345\u2013359","journal-title":"Curr Drug Targets"},{"key":"3768_CR35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1087-0024.2005.200407.x","volume":"10","author":"NK Haass","year":"2005","unstructured":"Haass NK, Herlyn M (2005) Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10:153\u2013163","journal-title":"J Investig Dermatol Symp Proc"},{"key":"3768_CR36","unstructured":"Picardo M (2010) In: Picardo M, Ta\u00efeb A (Hrsg) Vitiligo. Springer-Verlag, Berlin, S\u00a0339\u2013342"},{"key":"3768_CR37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1468-3083.2002.00407.x","volume":"16","author":"C Chiav\u00e9rini","year":"2002","unstructured":"Chiav\u00e9rini C, Passeron T, Ortonne JP (2002) Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 16:137\u2013138","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3768_CR38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1468-3083.2006.01420.x","volume":"20","author":"MS Kumaran","year":"2006","unstructured":"Kumaran MS, Kaur I, Kumar B (2006) Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 20:269\u2013273","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3768_CR39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.jidsp.5640189","volume":"4","author":"KU Schallreuter","year":"1999","unstructured":"Schallreuter KU, Moore J, Wood JM, Beazley WD, Gaze DC, Tobin DJ, Marshall HS, Panske A, Panzig E, Hibberts NA (1999) In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 4:91\u201396","journal-title":"J Investig Dermatol Symp Proc"},{"key":"3768_CR40","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/sj.jid.5700612","volume":"126","author":"NC Gibbons","year":"2006","unstructured":"Gibbons NC, Wood JM, Rokos H, Schallreuter KU (2006) Computer simulation of native epidermal enzyme structures in the presence and absence of hydrogen peroxide (H2O2): potential and pitfalls. J Invest Dermatol 126:2576\u20132582","journal-title":"J Invest Dermatol"},{"key":"3768_CR41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000246690","volume":"190","author":"KU Schallreuter","year":"1995","unstructured":"Schallreuter KU, Wood JM, Lemke KR, Levenig C (1995) Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 190:223\u2013229","journal-title":"Dermatology"},{"key":"3768_CR42","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00105-009-1916-9","volume":"61","author":"KU Schallreuter","year":"2010","unstructured":"Schallreuter KU, Salem MM (2010) Vitiligo. What is new? Hautarzt 61:578\u2013585","journal-title":"Hautarzt"},{"key":"3768_CR43","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1365-2133.2009.09252.x","volume":"161","author":"S Bakis-Petsoglou","year":"2009","unstructured":"Bakis-Petsoglou S, Le Guay JL, Wittal R (2009) A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 161:910\u2013917","journal-title":"Br J Dermatol"},{"key":"3768_CR44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/2279-042X.108375","volume":"1","author":"FF Naini","year":"2012","unstructured":"Naini FF, Shooshtari AV, Ebrahimi B, Molaei R (2012) The effect of pseudocatalase\/superoxide dismutase in the treatment of vitiligo: a pilot study. J Res Pharm Pract 1:77\u201380","journal-title":"J Res Pharm Pract"},{"key":"3768_CR45","first-page":"198","volume":"19","author":"C Galarza","year":"2009","unstructured":"Galarza C, Ramos W, Gutierrez EL, Or\u00e9 R, Ch\u00eda H, \u00c1vila J, Tello M, Ronceros G, Uribe M, G\u00e1mez D, Ortega-Loayza AG (2009) Efficacy and security of topical antioxidant therapy versus placebo in the treatment of vitiligo of recent onset. Dermatolog\u00eda Peruana 19:198\u2013204","journal-title":"Dermatolog\u00eda Peruana"},{"key":"3768_CR46","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/bjd.12587","volume":"169","author":"KU Schallreuter","year":"2013","unstructured":"Schallreuter KU (2013) Q10-triggered facial vitiligo. Br J Dermatol 169:1333\u20131336","journal-title":"Br J Dermatol"},{"key":"3768_CR47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2133.2006.07584.x","volume":"156","author":"CS Wu","year":"2007","unstructured":"Wu CS, Lan CC, Wang LF, Chen GS, Wu CS, Yu HS (2007) Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 156:122\u2013129","journal-title":"Br J Dermatol"},{"key":"3768_CR48","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/jid.2015.126","volume":"135","author":"NB Goldstein","year":"2015","unstructured":"Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, Robinson WA, Roop DR, Norris DA, Birlea SA (2015) Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol 135:2068\u20132076","journal-title":"J Invest Dermatol"},{"key":"3768_CR49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1172\/JCI0213729","volume":"110","author":"S Jamal","year":"2002","unstructured":"Jamal S, Schneider RJ (2002) UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. J Clin Invest 110:443\u2013452","journal-title":"J Clin Invest"},{"key":"3768_CR50","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.0906-6705.2004.00221.x","volume":"13","author":"CS Wu","year":"2004","unstructured":"Wu CS, Yu CL, Wu CS, Lan CC, Yu HS (2004) Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol 13:755\u2013763","journal-title":"Exp Dermatol"},{"key":"3768_CR51","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/0300060513516294","volume":"42","author":"N Karsli","year":"2014","unstructured":"Karsli N, Akcali C, Ozgoztasi O, Kirtak N, Inaloz S (2014) Role of oxidative stress in the pathogenesis of vitiligo with special emphasis on the antioxidant action of narrowband ultraviolet B phototherapy. J Int Med Res 42:799\u2013805","journal-title":"J Int Med Res"},{"key":"3768_CR52","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.ajpath.2011.02.016","volume":"178","author":"S Rana","year":"2011","unstructured":"Rana S, Rogers LJ, Halliday GM (2011) Systemic low-dose UVB inhibits CD8 T cells and skin inflammation by alternative and novel mechanisms. Am J Pathol 178:2783\u20132791","journal-title":"Am J Pathol"},{"key":"3768_CR53","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2133.2012.11008.x","volume":"167","author":"KK Park","year":"2012","unstructured":"Park KK, Liao W, Murase JE (2012) A review of monochromatic excimer light in vitiligo. Br J Dermatol 167:468\u2013478","journal-title":"Br J Dermatol"},{"key":"3768_CR54","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/09546634.2014.991268","volume":"26","author":"Y Sun","year":"2015","unstructured":"Sun Y, Wu Y, Xiao B, Li L, Li L, Chen HD, Gao XH (2015) Treatment of 308-nm excimer laser on vitiligo: a systemic review of randomized controlled trials. J Dermatolog Treat 26:347\u2013353","journal-title":"J Dermatolog Treat"},{"key":"3768_CR55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/phpp.12072","volume":"29","author":"S Bansal","year":"2013","unstructured":"Bansal S, Sahoo B, Garg V (2013) Psoralen-narrowband UVB phototherapy for the treatment of vitiligo in comparison to narrowband UVB alone. Photodermatol Photoimmunol Photomed 29:311\u2013317","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"3768_CR56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2230.2007.02514.x","volume":"32","author":"ML Dell\u2019Anna","year":"2007","unstructured":"Dell\u2019Anna ML, Mastrofrancesco A, Sala R, Venturini M, Ottaviani M, Vidolin AP, Leone G, Calzavara PG, Westerhof W, Picardo M (2007) Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol 32:631\u2013636","journal-title":"Clin Exp Dermatol"},{"key":"3768_CR57","unstructured":"Lu L, Wang S, Fu L, Liu D, Zhu Y, Xu A (2015) Bilobalide protection of normal human melanocytes from hydrogen peroxide-induced oxidative damage via promotion of antioxidase expression and inhibition of endoplasmic reticulum stress. Clin Exp Dermatol. [Epub ahead of print] PMID: 26178968"},{"key":"3768_CR58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2230.2003.01207.x","volume":"28","author":"D Parsad","year":"2003","unstructured":"Parsad D, Pandhi R, Juneja A (2003) Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 28:285\u2013287","journal-title":"Clin Exp Dermatol"},{"key":"3768_CR59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/2013.jamadermatol.386","volume":"149","author":"PE Grimes","year":"2013","unstructured":"Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW (2013) The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol 149:68\u201373","journal-title":"JAMA Dermatol"},{"key":"3768_CR60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","volume":"151","author":"HW Lim","year":"2015","unstructured":"Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M (2015) Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 151:42\u201350","journal-title":"JAMA Dermatol"},{"key":"3768_CR61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4103\/0378-6323.42905","volume":"74","author":"N Rath","year":"2008","unstructured":"Rath N, Kar HK, Sabhnani S (2008) An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad\/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol 74:357\u2013360","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"3768_CR62","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2014.12.003","volume":"14","author":"R Speeckaert","year":"2015","unstructured":"Speeckaert R, Speeckaert MM, van Geel N (2015) Why treatments do(n\u2019t) work in vitiligo: an autoinflammatory perspective. Autoimmun Rev 14:332\u2013340","journal-title":"Autoimmun Rev"},{"key":"3768_CR63","first-page":"92","volume":"18","author":"BB Gokhale","year":"1979","unstructured":"Gokhale BB (1979) Cyclophosphamide and vitiligo. Int J Dermatol 18:92","journal-title":"Int J Dermatol"},{"key":"3768_CR64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/archderm.1990.01670270071012","volume":"126","author":"AK Gupta","year":"1990","unstructured":"Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, Griffiths CE, Cooper KD, Voorhees JJ (1990) Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 126:339\u2013350","journal-title":"Arch Dermatol"},{"key":"3768_CR65","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/09546630600791442","volume":"17","author":"M Radmanesh","year":"2006","unstructured":"Radmanesh M, Saedi K (2006) The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 17:151\u2013153","journal-title":"J Dermatolog Treat"},{"key":"3768_CR66","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000433424","volume":"231","author":"H Singh","year":"2015","unstructured":"Singh H, Kumaran MS, Bains A, Parsad D (2015) A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo. Dermatology 231:286\u2013290","journal-title":"Dermatology"},{"key":"3768_CR67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000102044","volume":"215","author":"D Rigopoulos","year":"2007","unstructured":"Rigopoulos D, Gregoriou S, Larios G, Moustou E, Belayeva-Karatza E, Kalogeromitros D (2007) Etanercept in the treatment of vitiligo. Dermatology 215:84\u201385","journal-title":"Dermatology"},{"key":"3768_CR68","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjd.14016","volume":"173","author":"KC Webb","year":"2015","unstructured":"Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC (2015) Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo. Br J Dermatol 173:641\u2013650","journal-title":"Br J Dermatol"},{"key":"3768_CR69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/cei.12168","volume":"174","author":"A Ruiz-Arg\u00fcelles","year":"2013","unstructured":"Ruiz-Arg\u00fcelles A, Garc\u00eda-Carrasco M, Jimenez-Brito G, S\u00e1nchez-Sosa S, P\u00e9rez-Romano B, Garc\u00e9s-Eisele J, Camacho-Alarc\u00f3n C, Reyes-N\u00fa\u00f1ez V, Sandoval-Cruz M, Mendoza-Pinto C, L\u00f3pez-Colombo A (2013) Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol 174:229\u2013236","journal-title":"Clin Exp Immunol"},{"key":"3768_CR70","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"BG Craiglow","year":"2015","unstructured":"Craiglow BG, King BA (2015) Tofacitinib Citrate for the Treatment of Vitiligo: a Pathogenesis-Directed Therapy. JAMA Dermatol 151:1110\u20131112","journal-title":"JAMA Dermatol"},{"key":"3768_CR71","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134:2988\u20132990","journal-title":"J Invest Dermatol"},{"key":"3768_CR72","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1365-4632.2010.04694.x","volume":"51","author":"DY Lee","year":"2012","unstructured":"Lee DY, Choi SC, Lee DY (2012) A proposal for the treatment guideline in segmental vitiligo. Int J Dermatol 51:1274\u20131275","journal-title":"Int J Dermatol"},{"key":"3768_CR73","first-page":"37","volume":"74","author":"D Parsad","year":"2008","unstructured":"Parsad D, Gupta S, IADVL Dermatosurgery Task Force (2008) Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol 74:37\u201345","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"3768_CR74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000018089","volume":"198","author":"S Malakar","year":"1999","unstructured":"Malakar S, Dhar S (1999) Treatment of stable and recalcitrant vitiligo by autologous miniature punch grafting: a prospective study of 1,000 patients. Dermatology 198:133\u2013139","journal-title":"Dermatology"},{"key":"3768_CR75","first-page":"315","volume":"58","author":"SS Das","year":"1992","unstructured":"Das SS, Pasricha JS (1992) Punch grafting as a treatment of residual lesions of vitiligo. Indian J Dermatol Venereol Leprol 58:315\u2013319","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"3768_CR76","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/jdv.12647","volume":"29","author":"D Kovacs","year":"2015","unstructured":"Kovacs D, Abdel-Raouf H, Al-Khayyat M, Abdel-Azeem E, Hanna MR, Cota C, Picardo M, Anbar TS (2015) Vitiligo: characterization of melanocytes in repigmented skin after punch grafting. J Eur Acad Dermatol Venereol 29:581\u2013590","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3768_CR77","first-page":"685","volume":"12","author":"C Wassef","year":"2013","unstructured":"Wassef C, Lombardi A, Khokher S, Rao BK (2013) Vitiligo surgical, laser, and alternative therapies: a review and case series. J Drugs Dermatol 12:685\u2013691","journal-title":"J Drugs Dermatol"},{"key":"3768_CR78","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00042728-200802000-00005","volume":"34","author":"A Babu","year":"2008","unstructured":"Babu A, Thappa DM, Jaisankar TJ (2008) Punch grafting versus suction blister epidermal grafting in the treatment of stable lip vitiligo. Dermatol Surg 34:166\u2013178","journal-title":"Dermatol Surg"},{"key":"3768_CR79","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1046\/j.1365-2133.2002.04837.x","volume":"147","author":"MJ Olsson","year":"2002","unstructured":"Olsson MJ, Juhlin L (2002) Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Br J Dermatol 147:893\u2013904","journal-title":"Br J Dermatol"},{"issue":"3","key":"3768_CR80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bjd.12532","volume":"169","author":"SV Mulekar","year":"2013","unstructured":"Mulekar SV, Isedeh P (2013) Surgical interventions for vitiligo: an evidence-based review. Br J Dermatol 169(Suppl 3):57\u201366","journal-title":"Br J Dermatol"},{"key":"3768_CR81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4103\/0019-5154.57604","volume":"54","author":"R Falabella","year":"2009","unstructured":"Falabella R (2009) Vitiligo and the melanocyte reservoir. Indian J Dermatol 54:313\u2013318","journal-title":"Indian J Dermatol"},{"key":"3768_CR82","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/0974-2077.123408","volume":"6","author":"S Sacchidanand","year":"2013","unstructured":"Sacchidanand S, Thakur P, Purohit V, Sujaya SN (2013) Follicular unit extraction as a therapeutic option for vitiligo. J Cutan Aesthet Surg 6:229\u2013231","journal-title":"J Cutan Aesthet Surg"},{"key":"3768_CR83","first-page":"167","volume-title":"Pigmentary disorders: a comprehensive compendium","author":"S Dhar","year":"2014","unstructured":"Dhar S, Banerjee R, Malakar R (2014) Vitiligo in Children. In: Lahiri K, Chatterjee M, Sarkar R (Hrsg) Pigmentary disorders: a comprehensive compendium. Jaypee Brothers Medical Publishers(P) Ltd, New Delhi, S\u00a0167\u2013179"},{"key":"3768_CR84","first-page":"1043","volume":"30","author":"J Rao","year":"2004","unstructured":"Rao J, Fitzpatrick RE (2004) Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg 30:1043\u20131045","journal-title":"Dermatol Surg"},{"key":"3768_CR85","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1468-3083.2010.03876.x","volume":"25","author":"KM Alghamdi","year":"2011","unstructured":"Alghamdi KM, Kumar A (2011) Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol 25:749\u2013757","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3768_CR86","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1468-3083.2000.00038.x","volume":"14","author":"M Radmanesh","year":"2000","unstructured":"Radmanesh M (2000) Depigmentation of the normally pigmented patches in universal vitiligo patients by cryotherapy. J Eur Acad Dermatol Venereol 14:149\u2013152","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3768_CR87","first-page":"530","volume":"164","author":"V Eleftheriadou","year":"2011","unstructured":"Eleftheriadou V, Whitton ME, Gawkrodger DJ, Batchelor J, Corne J, Lamb B, Ersser S, Ravenscroft J, Thomas KS (2011) Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. Br J Dermatol 164:530\u2013536","journal-title":"Br J Dermatol"},{"key":"3768_CR88","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1348\/000711299160077","volume":"72","author":"L Papadopoulos","year":"1999","unstructured":"Papadopoulos L, Bor R, Legg C (1999) Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol 72:385\u2013396","journal-title":"Br J Med Psychol"},{"key":"3768_CR89","first-page":"55","volume":"17","author":"B Boone","year":"2007","unstructured":"Boone B (2007) Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 17:55","journal-title":"Eur J Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-016-3768-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-016-3768-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-016-3768-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T01:19:00Z","timestamp":1654391940000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-016-3768-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,24]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["3768"],"URL":"https:\/\/doi.org\/10.1007\/s00105-016-3768-4","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,24]]}}}